CLINICAL_TRIALS trial_result · 2020-12-17

Clinical Trial Update: Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients [Phase 2]

Phase 2 clinical trial update evaluating efficacy and safety of IBI308 in extranodal NK/T cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Effect of Drugs | Phase 2 | Status: COMPLETED | Results posted: 2020-12-17